DCT and melanoma: Additionally, both tyrosinase agonist 2-ETZ and tyrosinase substrate L-tyrosine significantly increased MITF, Tyrosinase, TYRP1 and TYRP2 expression and tyrosinase activity in parental B16 melanoma cells (Figure S2E-H and S2K-L).